Efficacy and safety of perampanel as the first add-on therapy for children with epilepsy: a real-world multicenter prospective observational study

Epilepsy is characterized by highly synchronized abnormal discharge of neuron groups. It is the most common neurological disease in children, and according to the World Health Organization, there were ∼50 million epilepsy patients worldwide in 2019 [1,2]. Epidemiological investigations showed that the prevalence of epilepsy in China was about 7.0‰ [2,3]. Anti-seizure medications (ASMs) remain the preferred choice for epilepsy treatment. In 2000, Kwan and Brodie reported in their prospective s tudy that ∼47% of newly diagnosed epilepsy patients can achieve a seizure-free state with monotherapy [4].
Source: Seizure: European Journal of Epilepsy - Category: Neurology Authors: Source Type: research